Dermata Therapeutics (NASDAQ:DRMA) Releases Earnings Results, Meets Estimates

Dermata Therapeutics (NASDAQ:DRMA) posted its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.55), FiscalAI reports. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.03 million.

Dermata Therapeutics Price Performance

Shares of DRMA traded down $0.01 during midday trading on Wednesday, hitting $0.70. The stock had a trading volume of 5,839 shares, compared to its average volume of 1,632,380. The firm has a market cap of $3.49 million, a price-to-earnings ratio of -0.16 and a beta of 0.63. Dermata Therapeutics has a twelve month low of $0.60 and a twelve month high of $4.66. The company has a 50 day simple moving average of $1.00 and a two-hundred day simple moving average of $1.27.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dermata Therapeutics in a research note on Monday, October 26th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions. Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin.